Halozyme Therapeutics | HALO - Equity Capital And Reserves

Stock Price
81.23
Daily Change
2.81 3.58%
Monthly
8.15%
Yearly
42.26%
Q1 Forecast
69.50

Halozyme Therapeutics reported $503.92M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.28B 85.22M Sep/2025
Alnylam Pharmaceuticals USD 233.89M 16.7M Sep/2025
Amarin USD 458.89M 6.03M Sep/2025
Amgen USD 9.62B 2.19B Sep/2025
Baxter International USD 7.24B 79M Sep/2025
Cytokinetics USD -521.12M 216.32M Sep/2025
DBV Technologies USD 52.85M 33.37M Sep/2025
Eli Lilly USD 23.79B 5.52B Sep/2025
Halozyme Therapeutics USD 503.92M 171.17M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
MannKind USD -44.55M 10.49M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
United Therapeutics USD 6.59B 583.4M Sep/2025